Short Interest in SAB Biotherapeutics, Inc. (NASDAQ:SABS) Grows By 21.1%

SAB Biotherapeutics, Inc. (NASDAQ:SABS) was the recipient of a significant growth in short interest during the month of March. As of March 13th, there was short interest totaling 1,953,472 shares, a growth of 21.1% from the February 26th total of 1,613,558 shares. Currently, 5.1% of the company’s stock are sold short. Based on an average trading volume of 918,838 shares, the days-to-cover ratio is presently 2.1 days.

Analysts Set New Price Targets

Several research analysts have recently commented on the stock. HC Wainwright dropped their price target on shares of SAB Biotherapeutics from $9.00 to $7.00 and set a “buy” rating on the stock in a research note on Tuesday, March 10th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of SAB Biotherapeutics in a research note on Monday, December 29th. Guggenheim started coverage on shares of SAB Biotherapeutics in a report on Friday, December 19th. They issued a “buy” rating and a $15.00 price objective for the company. Zacks Research downgraded shares of SAB Biotherapeutics from a “hold” rating to a “strong sell” rating in a research report on Thursday, March 12th. Finally, UBS Group started coverage on SAB Biotherapeutics in a report on Wednesday, January 7th. They set a “buy” rating and a $7.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $10.00.

SAB Biotherapeutics Stock Up 1.0%

Shares of SAB Biotherapeutics stock opened at $3.87 on Thursday. SAB Biotherapeutics has a 12-month low of $1.00 and a 12-month high of $6.60. The company has a quick ratio of 9.46, a current ratio of 9.46 and a debt-to-equity ratio of 0.02. The stock has a 50 day moving average price of $4.01 and a two-hundred day moving average price of $3.53. The stock has a market capitalization of $197.18 million, a P/E ratio of -1.67 and a beta of 0.60.

SAB Biotherapeutics (NASDAQ:SABS) last released its quarterly earnings results on Monday, March 9th. The company reported ($0.46) EPS for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.30). Equities analysts expect that SAB Biotherapeutics will post -3.69 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. ADAR1 Capital Management LLC bought a new stake in SAB Biotherapeutics during the third quarter valued at about $30,000. Dimensional Fund Advisors LP acquired a new stake in shares of SAB Biotherapeutics in the third quarter valued at about $32,000. State of Wyoming bought a new position in shares of SAB Biotherapeutics in the fourth quarter worth about $34,000. Virtu Financial LLC bought a new position in shares of SAB Biotherapeutics in the third quarter worth about $40,000. Finally, State Street Corp acquired a new position in shares of SAB Biotherapeutics during the 4th quarter worth about $49,000. Institutional investors own 7.82% of the company’s stock.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.